| My Account | Subscribe | Contact Us | Donate |
Home
- Kris Freeman Skis for Olympic Gold
- Good Insulin Injection Practices
- Etiquette for People without Diabetes
- Diabetes Technology and Intimacy
- An American in the UK: Healthcare for Type 1s
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Complications & Care Articles
Survey Says Most Endocrinologists and Physicians See a Need for More Byetta and Januvia-Type Drugs
High percentages of endocrinologists, primary care physicians, and managed care organizations surveyed by a research firm say they would like to see additional GLP-1 analogues like Amylin/Eli Lilly's Byetta® and DPP-IV inhibitors like Merck's Januvia® available to treat type 2 diabetes.
The survey, "A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors?," published by Waltham, Mass.-based Decision Resources, queried 77 primary care physicians, 72 endocrinologists, and 20 pharmacy directors of managed care organizations:
Regarding new GLP-1 analogues, 89 percent of the endocrinologists, 77 percent of the primary care physicians, and 75 percent of MCO pharmacy directors said they would like to have additional therapies available in that category.
Regarding DPP-IV therapies, 71 percent of the endocrinologists, 74 percent of the primary care physicians, and 70 percent of MCO pharmacy directors said they would like to see additional therapies offered in that category.
In explaining their answers, survey respondents indicated their concerns with Byetta and Januvia. They cited the need for frequent injections with Byetta (twice daily*) and its record of causing severe nausea in some patients. With Januvia, their concerns were with the drug's inability to lower glucose levels as well as the conventional diabetes drug metformin, and questions about its long-term safety.
The criteria respondents cited for adding new GLP-1 therapies included a less frequent need for injections and a lessening of nausea-producing effects. With DPP-IV therapies, they said that an increased ability to lower BG levels would favorably influence their decision to stock or prescribe new drugs in that category.
* A long-range version of Byetta, injected once weekly, is now under review by the FDA. The French pharmaceutical company Sanofi-aventis is currently conducting trials on its own version of exenatide, the generic form of Byetta.
Categories: Byetta, Complications & Care, Endocrinology, Health Care, Professional Issues, Type 2 Issues
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
6 comments -
Jul 25, 2009 -
Email to a Friend
Send a link to this page to your friends and colleagues.